학술논문

Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data
Document Type
Journal
Source
ANNALS OF ONCOLOGY; DEC 2018, 29 p25-p25, 1p. Supplement: 10
Subject
Language
English
ISSN
15698041